Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001776985-25-000039
Filing Date
2025-06-02
Accepted
2025-06-02 07:20:06
Documents
13
Period of Report
2025-06-02

Document Format Files

Seq Description Document Type Size
1 6-K form6-kbnt3272jun2025.htm 6-K 16359
2 EX-99.1 a991250602_bntxxbmsxprxcol.htm EX-99.1 32639
3 EX-99.2 a992atransformativegloba.htm EX-99.2 20015
4 a992atransformativegloba001.jpg GRAPHIC 87741
5 a992atransformativegloba002.jpg GRAPHIC 293305
6 a992atransformativegloba003.jpg GRAPHIC 270840
7 a992atransformativegloba004.jpg GRAPHIC 120404
8 a992atransformativegloba005.jpg GRAPHIC 87516
9 a992atransformativegloba006.jpg GRAPHIC 134178
10 a992atransformativegloba007.jpg GRAPHIC 122672
11 a992atransformativegloba008.jpg GRAPHIC 84139
12 image_0.jpg GRAPHIC 104097
13 image_1.jpg GRAPHIC 89114
  Complete submission text file 0001776985-25-000039.txt   1991068
Mailing Address AN DER GOLDGRUBE 12 MAINZ 2M 55131
Business Address AN DER GOLDGRUBE 12 MAINZ 2M 55131 0049613190840
BioNTech SE (Filer) CIK: 0001776985 (see all company filings)

EIN.: 000000000 | State of Incorp.: 2M | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39081 | Film No.: 251013128
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)